TNF and inflammatory bowel disease: They observed no significant differences in the crude incidence rates of IBD-related hospitalization, IBD-related surgery, and new corticosteroid use between patients treated with vedolizumab vs those treated with TNF antagonists, among all patients with IBD, or among subgroups of patients with CD or UC.